Opioid-Induced Bowel Dysfunction (OBD or OIBD) Pipeline Review, H1 2017 Featuring ChironWells, RaQualia Pharma & Vitality Biopharma - Research and Markets

DUBLIN--()--The "Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Pipeline Review, H1 2017" report has been added to Research and Markets' offering.

Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Opioid-Induced Bowel Dysfunction (OBD or OIBD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 3 and 3 respectively.

Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Overview
  3. Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Products under Development by Companies
  7. Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Therapeutics Assessment
  8. Assessment by Target
  9. Assessment by Mechanism of Action
  10. Assessment by Route of Administration
  11. Assessment by Molecule Type
  12. Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Companies Involved in Therapeutics Development
  • ChironWells GmbH
  • RaQualia Pharma Inc
  • Vitality Biopharma Inc

For more information about this report visit https://www.researchandmarkets.com/research/zgpnqp/opioidinduced

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Gastrointestinal Drugs , Addiction Disorders Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Gastrointestinal Drugs , Addiction Disorders Drugs